BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38285120)

  • 21. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
    Singh RR; Kunkalla K; Qu C; Schlette E; Neelapu SS; Samaniego F; Vega F
    Oncogene; 2011 Dec; 30(49):4874-86. PubMed ID: 21625222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma.
    Huang Q; Zhang F; Fu H; Shen J
    Epigenetics; 2021 Jan; 16(1):28-44. PubMed ID: 32600091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
    Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
    Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
    Hilton LK; Ngu HS; Collinge B; Dreval K; Ben-Neriah S; Rushton CK; Wong JCH; Cruz M; Roth A; Boyle M; Meissner B; Slack GW; Farinha P; Craig JW; Gerrie AS; Freeman CL; Villa D; Rodrigo JA; Song K; Crump M; Shepherd L; Hay AE; Kuruvilla J; Savage KJ; Kridel R; Karsan A; Marra MA; Sehn LH; Steidl C; Morin RD; Scott DW
    J Clin Oncol; 2023 Sep; 41(25):4164-4177. PubMed ID: 37319384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.
    Gaydosik AM; Queen DS; Trager MH; Akilov OE; Geskin LJ; Fuschiotti P
    Blood; 2020 Oct; 136(15):1748-1759. PubMed ID: 32438399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.
    Ling HY; Yang Z; Wang PJ; Sun Y; Ju SG; Li J; Fu JX
    Chem Biol Interact; 2022 Jan; 352():109779. PubMed ID: 34922904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-cell transcriptome sequencing provides insight into multiple chemotherapy resistance in a patient with refractory DLBCL: a case report.
    Zhao K; Li Q; Li P; Liu T; Liu X; Zhu F; Zhang L
    Front Immunol; 2024; 15():1303310. PubMed ID: 38533514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-4 up-regulation of epidermal interleukin-19 expression in keratinocytes involves the binding of signal transducer and activator of transcription 6 (Stat6) to the imperfect Stat6 sites.
    Bao L; Alexander JB; Shi VY; Mohan GC; Chan LS
    Immunology; 2014 Dec; 143(4):601-8. PubMed ID: 24943510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4
    Liu G; Luan J; Li Q
    DNA Cell Biol; 2016 Dec; 35(12):845-852. PubMed ID: 27704876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
    Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
    Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-mediated neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4(+) T cells.
    Deboy CA; Xin J; Byram SC; Serpe CJ; Sanders VM; Jones KJ
    Exp Neurol; 2006 Sep; 201(1):212-24. PubMed ID: 16806176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
    Higashi M; Tokuhira M; Fujino S; Yamashita T; Abe K; Arai E; Kizaki M; Tamaru J
    Leuk Lymphoma; 2016; 57(1):161-6. PubMed ID: 25860238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma.
    Wang J; Wang Y; Wan L; Chen X; Zhang H; Yang S; Zhong L
    Front Immunol; 2023; 14():1230017. PubMed ID: 37790933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs.
    Nesic M; Sønderkær M; Brøndum RF; El-Galaly TC; Pedersen IS; Bøgsted M; Dybkær K
    BMC Cancer; 2021 Jul; 21(1):829. PubMed ID: 34275438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6.
    Jiang L; Zhao XH; Mao YL; Wang JF; Zheng HJ; You QS
    J Exp Clin Cancer Res; 2019 Nov; 38(1):465. PubMed ID: 31718693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
    Broccoli A; Casadei B; Chiappella A; Visco C; Tani M; Cascavilla N; Conconi A; Balzarotti M; Cox MC; Marino D; Goldaniga MC; Marasca R; Tecchio C; Patti C; Musuraca G; Devizzi L; Monaco F; Romano A; Fama A; Zancanella M; Paolini R; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
    Oncologist; 2019 Sep; 24(9):1246-1252. PubMed ID: 30940746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
    Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
    Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
    Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
    Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.